Immutep Limited

Immutep Limited company information, Employees & Contact Information

Explore related pages

Related company profiles:

Immutep is a late-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. Its lead clinical candidate in oncology is eftilagimod alfa, a proprietary soluble LAG-3 protein and MHC Class II agonist that activates the immune system to fight cancer. In autoimmune diseases, Immutep's IMP761 is the world's first LAG-3 agonist antibody designed to target the underlying causes of autoimmune diseases. Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States. For more information, please visit www.immutep.com.

Company Details

Employees
52
Address
Level 33, Australia Square 264 George Street, Sydney,nsw 2000,australia
Phone
33169289992
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Sydney, NSW
Looking for a particular Immutep Limited employee's phone or email?

Immutep Limited Questions

News

Immutep Announces Successful Completion of FDA Project Optimus Requirements - Yahoo Finance

Immutep Announces Successful Completion of FDA Project Optimus Requirements Yahoo Finance

Immutep Limited Reports Positive Phase II Trial Results for Eftilagimod Alfa Combining with Radiotherapy in Soft Tissue Sarcoma - Quiver Quantitative

Immutep Limited Reports Positive Phase II Trial Results for Eftilagimod Alfa Combining with Radiotherapy in Soft Tissue Sarcoma Quiver Quantitative

Two Posters at ESMO Congress 2025 Highlight Immutep’s Focus - GlobeNewswire

Two Posters at ESMO Congress 2025 Highlight Immutep’s Focus GlobeNewswire

Immutep Shows 61.7% ORR in TPS - Stock Titan

Immutep Shows 61.7% ORR in TPS Stock Titan

Immutep Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alfa in Head and Neck Cancer with CPS - Yahoo Finance

Immutep Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alfa in Head and Neck Cancer with CPS Yahoo Finance

Immutep Announces Update for TACTI-004 (KEYNOTE-F91) Phase III Trial in First Line Non-Small Cell Lung Cancer - GlobeNewswire

Immutep Announces Update for TACTI-004 (KEYNOTE-F91) Phase III Trial in First Line Non-Small Cell Lung Cancer GlobeNewswire

Immutep Limited to Present TACTI-004 Phase III Trial Data at European Lung Cancer Congress 2025 - Nasdaq

Immutep Limited to Present TACTI-004 Phase III Trial Data at European Lung Cancer Congress 2025 Nasdaq

Immutep Announces Successful Completion of FDA Project Optimus Requirements - Stock Titan

Immutep Announces Successful Completion of FDA Project Optimus Requirements Stock Titan

Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the 2025 World Conference on Lung Cancer - Yahoo Finance

Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the 2025 World Conference on Lung Cancer Yahoo Finance

Immutep Limited Announces Transition to Phase III with Regulatory Approval for TACTI-004 Trial in Non-Small Cell Lung Cancer - Quiver Quantitative

Immutep Limited Announces Transition to Phase III with Regulatory Approval for TACTI-004 Trial in Non-Small Cell Lung Cancer Quiver Quantitative

First-Ever Neoadjuvant Efti Combo Trial in Soft Tissue Sarcoma: Immutep to Present Phase II Results - Stock Titan

First-Ever Neoadjuvant Efti Combo Trial in Soft Tissue Sarcoma: Immutep to Present Phase II Results Stock Titan

Immutep Announces Data from EFTISARC-NEO Phase II - GlobeNewswire

Immutep Announces Data from EFTISARC-NEO Phase II GlobeNewswire

Immutep’s Efti with KEYTRUDA® (pembrolizumab) & Chemotherapy Achieves High Response Rates in First-Line Non-Small Cell Lung Cancer - Yahoo Finance

Immutep’s Efti with KEYTRUDA® (pembrolizumab) & Chemotherapy Achieves High Response Rates in First-Line Non-Small Cell Lung Cancer Yahoo Finance

50-Patient Phase II Trial: Immutep's Efti Takes on Early-Stage Breast Cancer with GW Cancer Center - Stock Titan

50-Patient Phase II Trial: Immutep's Efti Takes on Early-Stage Breast Cancer with GW Cancer Center Stock Titan

Immutep’s Efti in Combination with KEYTRUDA® (pembrolizumab) Drives Strong Overall Survival in Head and Neck Cancer with CPS - Yahoo Finance

Immutep’s Efti in Combination with KEYTRUDA® (pembrolizumab) Drives Strong Overall Survival in Head and Neck Cancer with CPS Yahoo Finance

Leading Immunotherapy Firm Immutep Set for Key Healthcare Conference Series - Stock Titan

Leading Immunotherapy Firm Immutep Set for Key Healthcare Conference Series Stock Titan

Immutep Announces Research Collaboration with the George - GlobeNewswire

Immutep Announces Research Collaboration with the George GlobeNewswire

First Patient Dosed in Immutep’s TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer - GlobeNewswire

First Patient Dosed in Immutep’s TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer GlobeNewswire

First-in-Class Autoimmune Drug Achieves 80% T Cell Suppression in Breakthrough Phase 1 Results - Stock Titan

First-in-Class Autoimmune Drug Achieves 80% T Cell Suppression in Breakthrough Phase 1 Results Stock Titan

Immutep's Cancer Trial Shows Triple Therapy Boosts Tumor Response Rate by 233% in Sarcoma Study - Stock Titan

Immutep's Cancer Trial Shows Triple Therapy Boosts Tumor Response Rate by 233% in Sarcoma Study Stock Titan

Immutep Gains FDA Support for Eftilagimod Alfa Development in HNSCC Patients with Low PD-L1 Expression - Dermatology Times

Immutep Gains FDA Support for Eftilagimod Alfa Development in HNSCC Patients with Low PD-L1 Expression Dermatology Times

FDA Outlines Next Steps for Development of Eftilagimod Alfa in PD-L1–Negative HNSCC - OncLive

FDA Outlines Next Steps for Development of Eftilagimod Alfa in PD-L1–Negative HNSCC OncLive

Immutep Limited Advances Clinical Trials for Efti in Non-Small Cell Lung Cancer and Autoimmune Diseases, Reports Strong Financial Position - Quiver Quantitative

Immutep Limited Advances Clinical Trials for Efti in Non-Small Cell Lung Cancer and Autoimmune Diseases, Reports Strong Financial Position Quiver Quantitative

Frontline Eftilagimod Alpha/Pembrolizumab Yields Favorable OS in PD-L1–Negative HNSCC - OncLive

Frontline Eftilagimod Alpha/Pembrolizumab Yields Favorable OS in PD-L1–Negative HNSCC OncLive

Immutep tries again | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Immutep tries again | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Immutep Receives A$2.6 million R&D Tax Incentive from French Government - Yahoo Finance

Immutep Receives A$2.6 million R&D Tax Incentive from French Government Yahoo Finance

Immutep approaches Lag3 crunch time | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Immutep approaches Lag3 crunch time | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Study launches of eftilagimod alpha plus avelumab in urothelial cancer - Urology Times

Study launches of eftilagimod alpha plus avelumab in urothelial cancer Urology Times

Eftilagimod Alpha Plus Pembrolizumab Elicits Early Efficacy Signals in Metastatic HNSCC - OncLive

Eftilagimod Alpha Plus Pembrolizumab Elicits Early Efficacy Signals in Metastatic HNSCC OncLive

Why Immutep (IMMP) Is Among the Best Australian Stocks to Buy Now? - Yahoo Finance

Why Immutep (IMMP) Is Among the Best Australian Stocks to Buy Now? Yahoo Finance

Immutep Ltd Issues New Shares on ASX - TipRanks

Immutep Ltd Issues New Shares on ASX TipRanks

Eftilagimod Alpha Plus Pembrolizumab/Chemo Generates Improved Survival Trends in Advanced NSCLC - OncLive

Eftilagimod Alpha Plus Pembrolizumab/Chemo Generates Improved Survival Trends in Advanced NSCLC OncLive

Eftilagimod Alpha Plus Chemotherapy Lead-In Proves Safe in HR+/HER2-Low Breast Cancer - OncLive

Eftilagimod Alpha Plus Chemotherapy Lead-In Proves Safe in HR+/HER2-Low Breast Cancer OncLive

Immutep Granted New Patents in Japan and South Korea for - GlobeNewswire

Immutep Granted New Patents in Japan and South Korea for GlobeNewswire

Immutep confirms presentation of pivotal TACTI-004 trial at major international meeting - BiotechDispatch

Immutep confirms presentation of pivotal TACTI-004 trial at major international meeting BiotechDispatch

Immutep says 'Efti' INSIGHT-003 lung cancer trial reveals positive survival data - BiotechDispatch

Immutep says 'Efti' INSIGHT-003 lung cancer trial reveals positive survival data BiotechDispatch

Immutep reports topline results from TACTI-003 Phase 2b trial - BiotechDispatch

Immutep reports topline results from TACTI-003 Phase 2b trial BiotechDispatch

Immutep says its candidate in combination delivered positive efficacy and safety profile - BiotechDispatch

Immutep says its candidate in combination delivered positive efficacy and safety profile BiotechDispatch

Immutep (ASX:IMM): Set to commercialise its lung cancer treatment by 2027 - Stocks Down Under

Immutep (ASX:IMM): Set to commercialise its lung cancer treatment by 2027 Stocks Down Under

Immutep announces new collaboration with US-based LabCorp - BiotechDispatch

Immutep announces new collaboration with US-based LabCorp BiotechDispatch

Prima BioMed (IMMP) Stock Price, News & Analysis - MarketBeat

Prima BioMed (IMMP) Stock Price, News & Analysis MarketBeat

Top Immutep Limited Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant